Company / Total Assets
Corvus Pharmaceuticals, Inc. Total Assets History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$68.9M
FY2024
5-year range
$45.6M / $109.5M
FY2020-FY2024
Trend
+51.3%
vs FY2023
Sector context
#213 of 216
Health Care
What the data says
Among 216 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 1% for total assets. Total Assets returned to growth in FY2024 after 2 years of decline, reaching $69M.
Based on SEC 10-K filings.
$69M in FY2024 with a 5-year CAGR of -3.8%.
Remained stable around $69M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -14.3%
- 5-Year CAGR
- -3.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 216This company $68.9M Sector average $7.4B
▼
-99.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.8%, indicating a declining trend.
- In FY2024, total assets increased 51.3% year-over-year.
- Ranks #213 out of 216 companies in the Health Care sector.
- Peak total assets was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $68.9M | +51.3% |
| FY2023 | $45.6M | -33.2% |
| FY2022 | $68.2M | -37.7% |
| FY2021 | $109.5M | +28.0% |
| FY2020 | $85.5M | +2.3% |
| FY2019 | $83.6M | -29.3% |
| FY2018 | $118.2M | +24.8% |
| FY2017 | $94.8M | -32.4% |
| FY2016 | $140.2M | +42.3% |
| FY2015 | $98.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026